NCT02256930

Brief Summary

This is a single center, randomized, controlled, within subject comparison, multiple dose study to determine the sensitization potential of M518101 on normal skin under occlusive patch condition.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P75+ for phase_1 healthy-volunteers

Timeline
Completed

Started Sep 2014

Longer than P75 for phase_1 healthy-volunteers

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

September 30, 2014

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 6, 2014

Completed
26 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2014

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
Last Updated

August 11, 2015

Status Verified

August 1, 2015

Enrollment Period

2 months

First QC Date

September 30, 2014

Last Update Submit

August 7, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • inflammatory skin response score

    Drug application site will be evaluated for sign of inflammatory skin response (e.g. erythema, edema, papules)

    21 days

Study Arms (4)

M518101

EXPERIMENTAL

M518101 will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.

Drug: M518101

M518101 Vehicle

PLACEBO COMPARATOR

M518101 Vehicle will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.

Drug: M518101 Vehicle

Sodium lauryl sulfate

ACTIVE COMPARATOR

The sodium lauryl sulfate will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.

Other: Sodium lauryl sulfate

Saline

SHAM COMPARATOR

The saline will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.

Other: Saline

Interventions

M518101
M518101 Vehicle
Sodium lauryl sulfate
SalineOTHER
Saline

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Health male or female subjects are age 18 years or older
  • Signed and dated Informed Consent Form obtained prior to any study related activities
  • Subjects are free of any systemic or dermatologic disorder
  • For female, females of non childbearing potential or who agree to use a highly effective method of birth control during the study and have a negative urine pregnancy test
  • Subjects must be able to communicate with the investigator and understand and comply with the requirement of the study and visit schedule

You may not qualify if:

  • Have any visible skin disease at the application site which will interfere with the evaluation of the test site reaction
  • Have damaged skin in or around the test sites
  • Have a history of sensitivity to adhesive tape
  • Have a known sensitivity to constituents present in the material being evaluated
  • Have a history of, or are currently being treated for skin cancer
  • Have used any study drug and/or participate in any clinical study within 60 days prior to randomization
  • To engage in any type of strenuous exercise
  • Are pregnant, breastfeeding, or of childbearing potential and who wish to become pregnant during the study
  • Are deemed to be ineligible by the investigator

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

TKL research

Fair Lawn, New Jersey, 07410, United States

Location

MeSH Terms

Interventions

Sodium Dodecyl SulfateSodium Chloride

Intervention Hierarchy (Ancestors)

DodecanolFatty AlcoholsAlcoholsOrganic ChemicalsAlkanesulfonatesAlkanesulfonic AcidsSulfonic AcidsSulfur AcidsSulfur CompoundsLipidsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 30, 2014

First Posted

October 6, 2014

Study Start

September 1, 2014

Primary Completion

November 1, 2014

Study Completion

August 1, 2015

Last Updated

August 11, 2015

Record last verified: 2015-08

Locations